hotspot -WSS

hotspot

author：hotspot 2025-10-01 12:12:24 - browse：15652

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Fight over Supreme Court dialysis ruling puts kidney patients at risk

hotspot

WSS

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

CMS got Medicare Advantage quality rating wrong, judge rules

An outdated Medicare rule harms dementia patients with anxiety

Shifting the focus from loneliness to social health

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Sutter Health’s antitrust win overturned by appeals court

hotspot

hotspot

focus

Heart attack and stroke risk calculators need revising

HIV drugs protect against transmission, even in unprotected sex

Walensky prepares to leave CDC — and Congress — behind

Sutter Health’s antitrust win overturned by appeals court

Heart attack and stroke risk calculators need revising

Data don't support strong claims for Covid

Hepatitis C has a cure — but many Americans still lack access to it

STAT wants to know your pick for a great summer read or listen

The high cost of giving birth even with insurance

Fight over Supreme Court dialysis ruling puts kidney patients at risk

explore

Ultragenyx gene therapy for rare liver ailment succeeds in late

The most pressing bird flu mysteries scientists want answered

Ultragenyx gene therapy for rare liver ailment succeeds in late

'Little Tech' descents on D.C., wanting a say in how AI is regulated

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Structure Therapeutics oral GLP

hotspot

knowledge

entertainment

focus